Biotech Values

[DewDiligence]

PTLA -4%/PM on two deaths in phase-2 Cerdulatinib trial:

https://finance.yahoo.com/news/portola-pharmaceuticals-presents-interim-phase-123000957.html

Results also showed that cerdulatinib was generally well-tolerated in these heavily pre-treated patients (at target drug levels). However, three patients at 35 mg BID achieved higher than expected drug concentrations and had severe adverse events (SAEs) including two grade 5 infections and one case of grade three pancreatitis. The dose was subsequently reduced to 30 mg BID and a PK monitoring strategy was implemented.